Is Compounded Tirzepatide Still Legal?

Tirzepatide compounding grew explosively while the drug sat on the FDA's shortage list, and a lot of buyers now correctly sense something changed once it came off — but most explanations of what actually changed get the mechanism wrong. The real answer is in the statute, not in a rumor about a blanket ban.

Why did the shortage list matter for compounded tirzepatide?

Large-scale outsourcing-facility compounding — the 503B pathway that let compounders produce sizable batches of a drug that's essentially a copy of an approved product — is only legal for a copy drug while that drug sits on the FDA's official shortage list. The statute is explicit and, notably, strict about it: a 503B facility may compound a drug identical or nearly identical to an approved drug only if that drug "appears on the drug shortage list in effect... at the time of compounding, distribution, and dispensing"¹. That's not a grace period or a rolling allowance — it's tied to the drug's real-time shortage status. Once tirzepatide is no longer listed as in shortage, the statutory basis for mass 503B copy-compounding of it ends immediately, by the same law that opened the door in the first place. You can check tirzepatide's current, live shortage status yourself on the FDA's drug shortages database² rather than relying on any provider's claim about it.

What's still legal now that the shortage is over?

This is the part most "compounding is now illegal" takes miss entirely: 503B mass-copy compounding is not the only legal category. Traditional 503A pharmacy compounding operates under a different, narrower rule that was never tied to shortage status in the first place — a 503A pharmacy may compound a drug that isn't simply a copy of a commercially available product, specifically when a prescriber has determined a change made for an identified individual patient produces a significant difference for that patient³. In practice, that's the legal pathway that survives: a compounded dose, strength, or formulation genuinely tailored to an individual patient's documented needs — not a drug shortage — is what keeps 503A tirzepatide compounding legal on a patient-by-patient basis, even with tirzepatide off the shortage list.

What did the FDA propose in 2026?

The shortage list is one of two ways a 503B outsourcing facility can compound from a drug's raw ingredient. The other is the 503B bulks list: substances the FDA has found a "clinical need" for outsourcing facilities to compound with¹. On April 30, 2026, the FDA announced it proposes not to put tirzepatide, semaglutide or liraglutide on that list⁴, and the formal notice ran in the Federal Register on May 1, 2026 (document 2026-08552)⁵. The notice says the nominations didn't show anything about the approved tirzepatide products that makes them medically unsuitable for certain patients, which is the test the FDA uses for clinical need. It also says the agency doesn't count shortages or backorders as clinical need, because the shortage list is a separate route, and it notes that approved tirzepatide products were not on the shortage list as of the notice date⁵.

The comment period was set to close June 30, 2026 and was extended to July 30, 2026 by a second notice published June 26, 2026⁶. As of October 2026, no final decision has been published. The FDA says that after reviewing comments it may finalize the proposal as written or change it, and that it will publish the final determination in the Federal Register⁵. Two things are worth keeping straight. It is a proposal, not a final rule. And it covers 503B outsourcing facilities only; the 503A patient-specific route described above runs under a different section of the law and isn't what this notice addresses.

Why this isn't a scandal, and why the market didn't vanish

This is exactly the pattern the FDA's compounding framework is designed to produce: broad, shortage-driven compounding access when supply can't meet demand, narrowing back to individualized, prescriber-justified compounding once the approved product is reliably available. It's not evidence that the earlier compounded market was fraudulent — it was legal under the statute that applied at the time. It does mean the legal basis a provider can legitimately point to has changed, and a provider still marketing tirzepatide the way it did during the shortage, without being able to explain the current legal basis for what it's selling you, is a real red flag worth taking seriously — see the full legitimacy checklist for the verification signals that matter regardless of which molecule or which statutory pathway applies.

What should you ask a provider before you buy?

Ask directly: is this a 503A or 503B pharmacy, and if 503B, what legal basis does it use for tirzepatide now that the drug is off the shortage list? If it's 503A, ask what specific, documented individual difference justifies your compounded prescription rather than the FDA-approved product — a real answer to that question is exactly what the statute requires, and a provider that can't give you one isn't operating on solid legal ground. None of this makes compounded tirzepatide automatically unsafe or automatically illegal; it means the legal footing is narrower and more specific than it was during the shortage, and a transparent provider should be able to explain which pathway applies to your prescription. Compare verified, transparent providers on the cheapest tirzepatide ranking and price the alternative — brand-name Zepbound — using the true monthly cost framework before assuming compounded is automatically both the legal and the cheaper route for your situation. The statutory sources behind this are indexed in our research library. Not legal or medical advice — see our medical disclaimer; confirm current shortage status and your pharmacy's regulatory category directly.